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Prevalence of Pseudomonas aeruginosa (P. aeruginosa) and 
Antimicrobial Susceptibility Patterns at a Private Hospital in Sana'a, 
Yemen 
Background:Pseudomonasaeruginosa is clinically significant and opportunistic 
pathogenthat causes infections in hospitalized patients. Antibiotic resistance is a 
major concern in clinical practice. The ongoing emergence of resistant strains that 
cause nosocomial infections contributes substantially to the morbidity and mortality 
of hospitalized patients. 
Objective:To estimate the prevalence of Pseudomonasaeruginosaand antimicrobial-
resistant P. aeruginosaand the antimicrobial resistance patterns of P. 
aeruginosaclinical isolates from hospitalized patients. 
Methods: The study was performed at microbiology department of local hospital in 
Sana’a, Yemen. All the patients' samples of hospital departments from January, 2017 
to December, 2017 were included. A Total of 2079 samples were collected during the 
study period. Among them, 193 strains of Pseudomonas spp. were isolated. 
Results:  One hundred ninty three isolates of P. aeruginosawere isolated from 
different clinical specimens and fully characterized by standard bacteriological 
procedures. Antimicrobial susceptibility pattern of each isolates was carried out by the 
Kirby-Bauer disk diffusion method as per CLSI guidelines. Majority of P. 
aeruginosawere isolated from Sputum, followed by urine specimens. The isolate 
pathogen shows the highestsensitive to Meropenem (85.5%), followed by Amikacin 
(80.5%), Imipenem (80.0%), and Piperacillin/tazobactam (77.2). The highest 
frequency of resistance (96.2%) was observed with amoxicillin /clavulinic 
Acidfollowed by cefuroxime 94.6%, ampicillin/ sulbactam94.5%, Co-Trimoxzole 
80.5%, andnorfloxacin 54%. 
Conclusion: The result confirmed the occurrence of drug resistance strains of 
P.aeruginosa. Meropenem, imipenem, and amikacin, were found to be the most 
effective antimicrobial drugs. It therefore calls for a very judicious, 
appropriatetreatmentregimens selection by the physicians to limit the further spread of 
antimicrobial resistance P. aeruginosa. 
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1. Introduction: 
Pseudomonasaeruginosais clinically significant and opportunistic pathogenthat 
causes infections in hospitalized patients. In addition, most Pseudomonas specieshave 
intrinsic resistance to many antibiotics and ongoing emergence of new resistance can 
be developedafter commonly prescribed antimicrobial agents
(1)
.Pseudomonas 
aeruginosahas naturally resistant to many antibiotics due to thepermeability barrier 
afforded by its outer membrane lipopolysaccharide (LPS). Only few antibiotics are 
effective against Pseudomonasand even these antibiotics are not effective against all 
strains 
(2)
.Antibiotic resistance is a major concern in clinical practice. The resistant 
strains of Pseudomonas aeruginosathat cause nosocomial infections contributes 
substantially to the morbidity and mortality of hospitalized patients
(3)
. Despite the 
availability of a variety of effectiveantimicrobial agents, treatment of 
pseudomonalaeruginosa is often challenging
(4)
. Antimicrobial resistance is a growing 
problem worldwide, especially in hospitals, where resistant organisms are often first 
detected in ICUs
(5)
. The organism had been isolated from various infections like 
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respiratory tract infections, cystic fibrosis, ear infections, orthopaedic infections, 
urinary tract infections, surgical infections, severe burns, etc. It was also reported 
frequently from patients undergoing chemotherapy for neoplastic diseases
(6)
.The 
variations of antibiotic protocols in clinics or in regions result in the different 
resistance profiles
(4)
. It is, therefore, the goal of this study to determine the prevalence 
of P.aeruginosaisolates in a private hospital in Sana'a, Yemenalso to evaluate its 
susceptibility against certain antibiotics, as limited work has been previously 
conducted on this subject. 
2. Method: 
The study was performed at university of science and technology hospitalin Sana’a, 
Yemen. It is one of the major private hospitals in Yemen. All the patients' samples 
from January,2017 to December, 2017 were included. A Total of 2079 samples were 
gatheredduring the study period. Among them, 193 strains of Pseudomonas 
aeruginosawere isolated.The medicalrecords of these patients were retrieved and 
reviewed. All information regarding patients' gender andage as well as origin of 
clinical samples were collected. 
Antimicrobial susceptibility testing of all the Pseudomonas aeruginosaisolates was 
performed by Kirby-Bauer disk diffusion method and the result were interpreted by 
the Clinical Laboratory Standard Institute (CLSI) guidelines
(7)
. 
The antimicrobial susceptibility patterns of all the Pseudomonas aeruginosastrains 
were determined against the following antibiotics of standard strength:ceftazidime, 
amikacin, gentamicin, imipenem, meropenem, ciprofloxacin, cefoperazone, 
piperacillin/tazobactam,amoxicillin / clavulinic 
acid,moxifloxacin,cefepime,ceftizoxime,ampicillin/ sulbactam,cefuroxime, 
ceftriaxone,Co-Trimoxzole, and levofloxacin.Full ethical clearance was obtained from 
the qualified authorities who approved the study design.All data were analyzed using 
SPSS Statistics 21. Data was presented in tables and graphs. 
3. Result: 
According to result findings, there were more than half of Pseudomonasaeruginosa 
isolates in age group of 60 years and greater with 55(28%), followed by the age 
between 46 to 60 years in second rank about 38(20%), and finally the age between 31 
to 45 years only about 20(10%). In this study, Overall MRSA prevalence was 9.3 % 
(n=193/2079). 
Figure 1. Distribution of Pseudomonas aeruginosa isolates according to age. 
The figure 2 showed that there were about 154(80%) of Pseudomonas isolates form 
male, whereas the female had only about 39(20%). 
  
Figure 2.Distribution of Pseudomonasaeruginosa according to gender. 
 
According to the study results, the medical department had the highest prevalence of 
Pseudomonasaeruginosa isolates about 48(25%), followed by the intensive care unit 
in second rank about 41 (21%), the surgical department in third rank about 37(19%) 
and finally the pediatric and gynecology departments had only about 16(8%). 
 
Figure 3. Distribution of Pseudomonasaeruginosaisolates according to hospital 
departments. 
 
The figure 4 showed that the most of sample tests from sputum culture about 
82(42.5%), followed by the sample from urine culture in second rank about 
34(17.6%), and finally the sample test from other rout only about 6(3.1%). 
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Figure 4. Distribution of P.aeruginosaisolates according to sample types. 
 
According to the current study findings (table 1),more than half of medication was 
sensitive to P.aeruginosatest about 12 drugs (54.5%), whereas the medication that 
resistance to pseudomonas tests about 10 drugs (45.5%). 
Pseudomonasaeruginosa strains showed resistance to ciprofloxacin 50.89%, 
ceftazidime 31.5%, ceftriaxone 78%, amoxicillin /clavulinic Acid 96.2%,ampicillin/ 
sulbactam 94.5%, cefuroxime 94.6%, nalidixic acid 83%, nitrofurantoin 88%, 
doxycycline 82.6%,norfloxacin 54%,and Co-Trimoxzole 80.5%. The highest 
frequency of sensitivity (85.5%) was observed with meropenem followed by amikacin 
80.5%, imipenem 80%, piperacilline/tazobactam 77.2%, ceftizoxime 75%, 
ciprofloxacin 71.5%, levofloxacin 66%, cefoperazone 64%, gentamicin 56%, 
ceftazidime 54.5%, moxifloxacin 49%, and cefepime 44.5%. 
 
 
Table 1. Antimicrobial susceptibility patterns for P.aeruginosaisolates 
 
Antibiotics 
Expected 
options 
Response  
Antibiotics 
Expected 
options 
Response 
F % F % 
Ceftriaxone 
S 11 18.5% 
Ceftazidime 
S 103 54.5% 
R 46 78% R 60 31.5% 
I 2 3.5% I 26 14% 
Cefoperazone /
sulbactam 
S 58 64% 
Ciprofloxaci
n 
S 118 71.5% 
R 27 29.5% R 40 24% 
I 6 6.5% I 7 4.5% 
Levofloxacin 
S 108 66% 
Co-
Trimoxzole 
S 37 19.5% 
R 44 26.8% R 152 80.5% 
I 12 7.2% I 0 0.0% 
ampicillin/ 
sulbactam 
S 2 3.7% 
Imipenem 
S 150 80% 
R 51 94.5% R 29 15.4% 
I 1 1.8% I 9 4.6% 
Amoxicillin / S 4 2.1% Norfloxacin S 10 38.5% 
 Clavulinic Acid R 179 96.2% R 14 54% 
I 3 1.7% I 2 8% 
Amikacin 
S 152 80.5% 
Cefepime 
S 83 44.5% 
R 28 14.8% R 81 43.5% 
I 9 4.7% I 22 12% 
Gentamicin 
S 105 56% 
Meropenem 
S 89 85.5% 
R 65 35% R 10 9.5% 
I 17 9% I 5 5% 
Moxifloxacin 
S 77 49% 
Piperacillin/ 
tazobactam 
S 146 77.2% 
R 69 44% R 31 16.5% 
I 11 7% I 12 6.3% 
Cefuroxime 
S 8 4.2% 
ceftizoxime 
S 1 4% 
R 178 94.6% R 18 75% 
I 2 1.2% I 5 21% 
 
According to figure 5 below, the highest resistance rate of anti-pseudomonal agent 
was with cefepime about 43.5% and the lowest resistance rate with 
imipenem.Resistance to antipseudomonal drugs in our study was found to be 
cefepime (43.5%), ceftazidime (31.5%), ciprofloxacin (24%), piperacillin  / tazobactam 
(16.5%), imipenim (15.4%).In the present study, multidrug resistance (MDR) rate 
(resistance to three or more of anti-Pseudomonal antimicrobials (i.e. piperacillin + 
tazobactam, imipenem, ceftazidime and amikacin) was determined to be 4.2% 
(8/193). Also MDR rate for only three anti Pseudomonal antimicrobials without 
imipenem was 4.2% (n= 8/193) (i.e. piperacillin + tazobactam, ceftazidime and 
amikacin) 
 
Figure 5. Resistance rates of anti-pseudomonal agents. 
 
4. Discussion: 
Pseudomonasaeruginosa has defined as one of the most common nosocomial 
pathogens. Hence we have undertaken this study to analyse the prevalence and 
antimicrobial susceptibility pattern of pseudomonas aeruginosa from various clinical 
samples of a private hospital.Periodic antimicrobial resistance monitoring in P. 
aeruginosais fundamental to updating the current activity level of commonly used 
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 antipseudomonal drugs.The present study measures the rate of isolation of 
pseudomonas aeruginosa(n=193/2079; 9.3%) as which is lower than previous studies 
as by Tadvi et al.
 (8)
 (22.67%) and Viren et al 
(9)
. 
The occurrence of P.aeruginosawas found to be higher in males, inpatients in age 
group >60 years and in surgery department, which is same as reported by Marzoqiet 
al.
 (10)
. This might be due to prolonged hospitalization and other associated co-
morbidities in these age groups.The distribution of pseudomonasaeruginosa isolates 
specimens may vary with each hospital as each hospital and each health facility has a 
different environment associated with it. According to the study results, more than 
42.5% of the pseudomonas aeruginosaisolates were obtained from sputum samples.  
The distribution rank of the isolates according to the types of specimens was 
(respiratory sputum > urine > blood > pus >wound swap > others). Respiratory 
isolates (42.5%) were the most frequently encountered. P. aeruginosaisolates from 
respiratory tract as observed in a similar study of inpatient isolates done in a Saudi 
Arabian hospital
(11)
. In the present study, the maximum clinical isolates of P. 
aeruginosawere isolated from medical department (25%), followed by ICU (21%) & 
surgical department (19%). This wassimilar to study of Pathmanathan SG
(12)
. The 
distribution of specimens of Pseudomonas aeruginosamight vary with each hospital 
as each hospital facility has a different environment associated with it.The correlation 
between specimen type and multidrug resistance would have been more noteworthy if 
supported by data on patients’ clinical conditions.Prevalence of infection was higher 
in medical ward followed by ICU as maximum isolates were isolated from sputum 
samples. According to vancomycin and linezolide usage there was no significant 
correlation between drug resistance and the wards from which isolates originated. 
However, there was statistical significant relationship between the 
piperacilline/tazobactam susceptibility and sample types (P value= 0.04). On other 
hand, there was no statistical significant relationship between the other antibiotics 
susceptibility (ceftazidime, imipenem, cefipeme) and sample types.As with this study, 
P. aeruginosa infection was primarily noted among older adults (n = 55, 28%) 
particularly respiratory infection (n = 82, 42.5%). There are a number of reasons why 
older adults are burdened by this type of infection. These include age-associated 
impairments in immunity that lead to reduced response to vaccination, a constellation 
of chronic and comorbid diseases, and functional limitations associated with advanced 
age. Additionally, older adults are at risk for aspiration pneumonia, outbreaks of 
gastroenteritis, recurrent urinary tract infection, and prosthetic device infections 
(13)
.In 
the European Prevalence of Infection in Intensive Care (EPIC), P.aeruginosa was 
predominant gram-negative bacteria isolated from bronchopulmonary infections and 
accounts for 17% of health care-associted pneumonia and late–onset ventilate 
associated pneumonia 
(14)
and accounts for significant cases of cystic fibriosis
(15)
.The 
distribution of isolates differs with studies and clinical specimens
(16)
.Intensive care 
patients especially create an environment for infection because of the debilitating 
effect of a prolonged hospitalisation and the application of medical equipment 
(airways, catheters etc) 
(17)
.ICUs are generally considered epicenters of antibiotic 
resistance and the principal sources of outbreaks of multi-resistant bacteria. The most 
important risk factors are excessive consumption of antibiotics exerting selective 
pressure on bacteria, the frequent use of invasive devices and relative density of a 
susceptible patient population with severe compelling diseases
(18)
. Thus, in ICUs, 
empirical antibiotic treatments should be avoided and treatment should be carried out 
using antibiotic susceptibility tests. ICUs should be regularly monitored resistance 
 pattern against the various antibiotics. P. aeruginosawas responsible for pneumonia 
and septicaemia with deaths rate about 30% in immunocompromised patients 
(19).
 
In the current study results, Pseudomonasaeruginosa showed resistance to amoxicillin 
/clavulinic Acid 96.2%,ampicillin/ sulbactam 94.5%,cefuroxime 94.6%, nalidixic acid 
83%, nitrofurantoin 88%, doxycycline 82.6%,ciprofloxacin 50.89%, ceftazidime 
31.5%, ceftriaxone 78%, norfloxacin 54%,and Co-Trimoxzole 80.5%. However, the 
highest frequency of sensitivity (85.5%) was observed with meropenem followed 
byamikacin 80.5%, imipenem 80%, piperacilline/tazobactam 77.2%,ceftizoxime 75%, 
ciprofloxacin 71.5%, Levofloxacin 66%,Cefoperazone 64%, Gentamicin 56%, 
ceftazidime 54.5%,moxifloxacin 49%, and cefepime 44.5%.This may be explained by 
the fact that routine use of these antibiotics can lead to clinically significant 
resistance. One remarkable finding in the present study was the highest frequency of 
sensitivity (85.5%) was observed with meropenem, 85.5%, amikacin (80.5%), and 
piperacillin/tazobactem (77.2%). These drugs were the most effective drugs against 
P.aeruginosa infections. This similar to study finding byTaranasarwat et al.
(20)
, who 
reported highest sensitivity to imipenam. Also it was quite similar to the findings of 
Shaikh et al (100%)
(21)
and Mohan et al., (94.3%)
(22)
. One striking feature in this study 
was that all the P. aeruginosaisolates were found to be sensitive to imipenem. This 
may be due to the restricted use of imipenem in this hospital. This is consistent with a 
report published in 2002 in Mangalore, India
(23)
. The emergence of carbapenem 
resistance is a serious concern 
(24)
. In various studies across the world, varying rates of 
resistance from 4-60% have been reported for imipenem and meropenem
(25)
. Another 
survey found that resistance to imipenem was 19%, while other studies have reported 
low rates (5.8% and 9%) and high rates (38.6%) of resistance to 
imipenem
(26)
.Piperacillin+ tazobactam showed a sensitive rate of 77.2 % in this study 
and cefoperazone-sulbactum showed a lower resistance of 29.5% only, indicating 
beta-lactamase inhibitor markedly expands the spectrum of activity of beta-lactams, 
which makes the combination drug the preferred choice against 
Pseudomonasaeruginosa infections. Thus, emphasis should be given towards use of 
combined antibiotics in the treatment of pseudomonal infections 
(27)
. Bayani et al. 
found that the resistance rate of P. aeruginosato amikacin, ceftazidime, cefepime, 
imipenem,and ciprofloxacin was 53.3%, 43.3%, 40%,40%, and 33.3%, respectively, 
and the prevalence of P. aeruginosaresistant isolates has increased
(28)
.According to 
previous evidence, the rate of susceptibility was most productive for antimicrobial 
agent of class carbapenem against Pseudomonasaeruginosa
(29)
Supported current 
results as 85.5% of strains were susceptible to Meronem and 80% to imipenem of 
class carbapenems. Although the resistance to carbapenems that include imipenem 
(16%) and meropenem (17.1) was low in this study, quite alarming should take into 
account that carbapenems are the last line of antibiotics for treating Gram-negative 
bacilli infections. Resistance to carbapenems may be due to a result of complex 
interactions of several mechanisms including production of carbapenemase, 
overproduction of efflux system and loss of outer membrane porins. P. aeruginosa 
isolates that are carbapenem resistant, specifically carbapenemase producing, are the 
worst, for the reason that they are associated with a higher mortality rate 
(24)
.Amikacin 
in this study was noted to be the most effective drug(80.5% sensitive). However, it is 
not commonly prescribed drug, because of its numerous side effects including renal 
toxicity, blurred vision, hearing loss, Bartter-like syndromes
(30)
, neuromuscular 
blockade, arthralgia, and apnoea. In addition, ciprofloxacin (71.5% sensitive) proved 
to be within the most effective drugs for routine use among the P. aeruginosastrains 
investigated in this study. The result finding in this study was similar in a previous 
 study finding that reported that amikacinhad the highest sensitivity against P. 
aeruginosa
(9)
.Also in France, a higher susceptibility rate of 86% of amikacin was 
reported by Cavallo et al. 
(31)
.An earlier study reported from Kathmandu, Nepal 
(32)
shown amikacin (81.4% sensitive) and ciprofloxacin (70.3% sensitive) among P. 
aeruginosastrains examined. Amikacin seems to be a promising therapy for 
pseudomonal infection. Hence, its use should be restricted to severe nosocomial 
infections, in order to avoid rapid emergence of resistant strains
(33)
.However, high 
resistance to aminoglycosides had been reported in studies done in Bangladesh 
(34)
, 
Turkey 
(4)
 and Malaysia 
(35)
.Similarly, higher rates of resistance to fluoroquinolones 
such as ciprofloxacin resistance (92%) were shown in a study from Malaysia 
(36)
.Also 
study findings by Zhanel et al. 
(37)
reported moxifloxacin 58% and ciprofloxacin 
46.7%.Because of the increasing resistance to fluroquinolone in many hospitals, its 
empirical usage is either banned or restricted, to bring the developing resistance rates 
under control.Recently, ceftazidime and cefepime are the most frequently prescribed 
third and fourth generation cephalosporins respectively. Ceftadizime is known 
antipseudomonal drug that has demonstrated high susceptibility pattern with P. 
aeruginosa isolates. The increased prevalence of ceftazidime resistant P.aeruginosa is 
related to the increased use of beta lactam antibiotics such as amoxicillin and 
ceftazidime.However, the resistance to cefadizime was reported as 31.5% in this 
study. This value of resistance waslessthan reported from Gujarat, with a resistance 
value of 75% 
(9)
. P. aeruginosastrains in this study exhibited a high rate of resistance 
to the third generation cephalosporin drug such as ceftriaxone (78%). A much higher 
resistance to ceftriaxone of 75%, 86% and 93.9% had been reported in studies done in 
India 
(38)
Bangladesh 
(34)
and Nepal 
(27)
.Several studies have confirmed that 
Pseudomonas aeruginosawas mostly resistant against ceftriaxone. However, this high 
level of resistance is not quite surprising as some suggest that ceftriaxone has 
considerably low activity against P. aeruginosa
(39,40)
.Another study reported the 
following rates of resistance to cefepime 64.8%, piperacilline/tazobatctam45%, 
ciprofloxacin 38.9%, levofloxacin 36.1%, gentamicin 37.3% and amikacin 30% 
(41)
.Relatively low piperacilline/tazobactam resistance (11.5%) had been reported in a 
hospital isolates of P. aeruginosain a study from Saudi Arabia 
(11)
. In a study done in 
Kathmandu, Nepal 
(27)
, P. aeruginosaisolates obtained from intensive care unit of a 
national heart centre showed a high cefoperazone-sulbactum sensitivity rateof 
84.8%.A previous study discovered an increased mortality rate associated with 
empiric piperacillin-tazobactam therapy given to patients with P. 
aeruginosabacteraemia; the isolates had reduced piperacillin-tazobactam 
susceptibility 
(42)
.In this study, amoxicillin /clavulinicacid had established 96.2 % 
resistance. Similarly, in a study conducted in Pakistan reported by Khan et al. 
(43)
had a 
high resistance rate of penicillin that is 98%; our findingsare also in agreement with 
other studies as reported bySasirekha et al. 
(44)
and Ullah et al. 
(45)
with respect to 
penicillin’s. Also the same findings were obtained with amoxicillin /clavulinic acid 
(1.88%) and showed increasing resistance. Multi drug efflux pumps in the inner and 
outer membrane of Ps. aeruginosamay protect the bacterium from β-lactam 
agents
(46)
.Similar pattern had been reported in study in Nigeria 
(47)
. In addition, 
susceptibility to fourth-generation such as cefepime reported in India 32% 
(48)
 and in 
Bulgaria 42% 
(49)
against Pseudomonas aeruginosa isolates. The high resistance to 
cephalosporins may be due to production of extended spectrum β-lactamases by the 
bacteria involved
(50)
.Cefuroxime was one of the cephalosporin drugs tested in this 
study, with resistance value of 94.6%. These high resistance value observed were 
comparable with the report from Gujarat, India with resistance value of 73.2% 
(9)
, but 
 higher than reports from Malaysia of 40% 
(51)
.Selective pressure from the use of 
antimicrobial agents is a major determinant for the emergence of resistant strains.The 
rate of resistance for the anti-folate drug co-trimoxazole in the present study was 
80.5%. In similar to previous study done in Bangladesh 
(34)
showed rate of resistance 
for co-trimoxazole to be 93.5% in wound swab and pus isolates of P. aeruginosawhile 
a Nigerian study 
(52)
showed P. aeruginosaisolates 100% resistant to co-
trimoxazole.According to resistance rates of antipseudomonal agents, imipenem and 
piperacillin  / tazobactam were found to be effective when compared to Ceftazidime, 
cefepime, and Ciprofloxacin. So, imipenem which is both an anti-pseudomonal drug 
and carbapenem was the best drug.According tothe study findings, MDR rate 
(resistance to three or more of anti Pseudomonal antimicrobials (i.e. piperacillin + 
tazobactam, imipenem, ceftazidime and amikacin) was determined to be 4.2% 
(8/193). Also MDR rate for only three anti Pseudomonal antimicrobials without 
imipenem was 4.2% (8/193) (i.e. piperacillin + tazobactam, ceftazidime and 
amikacin)A study done by Unan et al.
(53)
.in Turkey reported rates of MDR, which 
were as high as 60%, whereas study done by Sabir et al., in Pakistan detected lower 
rates of MDR (22.08%)
(54)
. However, the rates of our study are comparable to a study 
done in Egypt, where Gad et al.
(55)
observed 36% MDR P. aeruginosa.On comparing 
the sensitivity patterns of these antimicrobials, it was found that there was a 
considerable difference in the sensitivity pattern among these studies. This indicates 
that the sensitivity pattern changes from hospital to hospital and population to 
population. Also nowadays the common antimicrobial agents are losing their efficacy 
against pathogens like Ps.aeruginosa. This has been possibly resulted from 
indiscriminate use of antibiotic, lack of awareness, patient non-compliance and 
unhygienic conditions 
(56)
.According to Berglund 
(57)
one of the reasons for resistance 
among bacteria is a result of either overuse and misuse of antibiotics. By misuse, this 
refers to the prescription of antibiotics without establishing bacterial infection, and the 
non-compliance of the patient to the full prescription. Moreover, antibiotic resistance 
can also be transferred horizontally between bacteria. 
The currentstudy resultsindicated that P. aeruginosawas becoming resistant to 
commonly used antibiotics due to excessive consumption of antibiotics exerting 
selected pressure on bacteria, frequently used invasive devices and severs under 
laying diseases. The empirical antibiotic treatment should be limited and treatment 
should be carried out using antibiotic susceptibility test and efforts should be made to 
prevent spread of resistant bacteria
(56)
. 
5. Conclusion: 
In conclusion, results of the present study clearly demonstrated the occurrence of 
resistance to various antipseudomonal agents among the pseudomonas 
aeruginosaisolates. The statistics in this study showed low rates of antibiotic 
resistance to meropenem, amikacin, and meropenem, and piperacillin/tazobactam and 
maximum sensitivity against pseudomonas aeruginosa strains. We suggest a more 
restricted and a more rational use of these drugs in hospital setting in order to avoid 
rapid emergence of resistant strains. Regular anti-microbial susceptibility monitoring 
is essential of local, regional and national level isolates. This would held and guide 
the physicians in prescribing the right. Every effort should be made to prevent spread 
of resistant organisms. The solution can be planned by continuous efforts of 
microbiologist, clinician, pharmacist and community to promote greater 
understanding of this problem. Frequent hand washing to prevent spread of organism 
should be encouraged. Better surgical and medical care should be provided to patients 
during hospital stay. 
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